NCT04764864

Brief Summary

Pelvic fracture is a usual injury in trauma patients. An unstable trauma patient with a pelvic fracture has an elevated risk of death due to pelvic bleeding and the associated injuries. Traditionally, it has been estimated that the main source of bleeding is venous and, consequently, the main treatment has been the preperitoneal pelvic packing. Nevertheless, according to new data, arterial bleeding appears to be a more important source of pelvic bleeding than it was thought and angioembolization seems to be a good alternative in the treatment of these injuries. Consequently, it is important to define better the management of these patients. This investigation project consists in a clinical trial study, performed by a multidisciplinary team of many hospitals around the country, in which angioembolization and preperitoneal pelvic packing are compared. Unstable trauma patients with a pelvic fracture and no other injuries (negative FAST / peritoneal aspiration, no evidence of bone fractures or thoracic injuries) will be submitted, in less than 60 minutes from hospital arrival, to angioembolization or preperitoneal pelvic packing, according to randomization. There will be a specific timing evaluation of different markers: hemodynamic (vital signs at arrival, immediately and 24 hours after treatment) and analytic (at arrival and upon entering to the Intensive Care Unit). Registered variables include: blood cell transfusions, vasoactive drug requirements, time elapsed between hospital admission and intervention, treatment duration, need of other strategies to stop pelvic bleeding, complications and mortality. The objective of this study is to determinate if angioembolization is superior to preperitoneal pelvic packing for pelvic bleeding control in unstable trauma patients due to pelvic bleeding.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2022

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 16, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 21, 2021

Completed
10 months until next milestone

Study Start

First participant enrolled

January 1, 2022

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

January 19, 2022

Status Verified

January 1, 2022

Enrollment Period

Same day

First QC Date

February 16, 2021

Last Update Submit

January 4, 2022

Conditions

Keywords

TraumaPelvis FractureHypovolemic ShockPreperitoneal Pelvic PackingAngioembolizationHemodynamic Instability

Outcome Measures

Primary Outcomes (1)

  • Pelvic bleeding control based on clinical response

    Clinical response after the intervention

    24 hours

Secondary Outcomes (7)

  • Additional techniques

    Through study completion, an average of 2 years

  • Post-procedure complications

    Through study completion, an average of 2 years

  • Post-procedure complications degree

    Through study completion, an average of 2 years

  • Post-procedure complications degree

    Through study completion, an average of 2 years

  • Mortality

    Through study completion, an average of 2 years

  • +2 more secondary outcomes

Other Outcomes (7)

  • Time until arrival at hospital

    Time until arrival at hospital (up to 30 minutes)

  • Duration of angioembolization

    Through study completion, an average of 2 years

  • Angioembolization treatment

    Through study completion, an average of 2 years

  • +4 more other outcomes

Study Arms (2)

Angioembolization

ACTIVE COMPARATOR
Procedure: Angioembolization

Preperitoneal Pelvic Packing

ACTIVE COMPARATOR
Procedure: Preperitoneal Pelvic Packing

Interventions

Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed. In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated. The material used will vary depending on the characteristics of the injury and the availability of the materials.

Angioembolization

Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified. Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect. A second intervention is required to remove the material in 24-48 hours.

Preperitoneal Pelvic Packing

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Systolic blood pressure ≤ 90 mmHg
  • Heart rate \> 100 bpm
  • Shock Index ≥ 0,8
  • Pelvic fracture
  • Negative FAST / peritoneal aspiration

You may not qualify if:

  • Other causes of bleeding that require treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Corporació Sanitària Parc Taulí

Sabadell, Barcelona, 08208, Spain

Location

MeSH Terms

Conditions

Wounds and InjuriesHip FracturesShock

Condition Hierarchy (Ancestors)

Femoral FracturesFractures, BoneHip InjuriesLeg InjuriesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Nuria Llorach-Perucho, MD

    Corporacion Parc Tauli

    PRINCIPAL INVESTIGATOR
  • Salvador Navarro-Soto, MD, PhD

    Corporacion Parc Tauli

    STUDY DIRECTOR
  • Andrea Campos-Serra, MD

    Corporacion Parc Tauli

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 16, 2021

First Posted

February 21, 2021

Study Start

January 1, 2022

Primary Completion

January 1, 2022

Study Completion

January 1, 2022

Last Updated

January 19, 2022

Record last verified: 2022-01

Locations